Jefferies Sticks to Their Buy Rating for Dexcom (DXCM)
Jefferies analyst maintained a Buy rating on Dexcom today and set a price target of $112.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Jefferies, Dexcom also received a Buy from TipRanks – OpenAI’s OpenAI Medical – Devices in a report issued on February 27. However, on the same day, TipRanks – Anthropic reiterated a Hold rating on Dexcom (NASDAQ: DXCM).
Based on Dexcom’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.26 billion and a net profit of $267.3 million. In comparison, last year the company earned a revenue of $1.11 billion and had a net profit of $151.7 million
Read More on DXCM:
Disclaimer & DisclosureReport an Issue
- Dexcom Adds Google Executive Rick Osterloh to Board
- DexCom management to meet virtually with BTIG
- Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value
- DexCom Earnings Call Highlights Margin Rebound, Growth
- Early notable gainers among liquid option names on February 13th
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.